Naringenin enhances the efficacy of ferroptosis inducers by attenuating aerobic glycolysis by activating the AMPK-PGC1α signalling axis in liver cancer

• Published in: Heliyon 2024-06, Vol.10 (11), p.e32288, Article e32288
• Main Authors: Li, Yong-Zhuo, Deng, Jing, Zhang, Xiao-Dong, Li, Dong-Yang, Su, Li-Xi, Li, Shan, Pan, Jian-Min, Lu, Lan, Ya, Jia-Qi, Yang, Nuo, Zhou, Jing, Yang, Li-Hui
• Format: Article
• Language: English
• Subjects: Aerobic glycolysis; AMPK-PGC1α signalling axis; cytotoxicity; Ferroptosis; glycolysis; hepatocytes; lipid metabolism; lipid peroxidation; Liver cancer; liver neoplasms; Naringenin; neoplasm cells; phenotype; synergism; translational value; xenotransplantation
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e32288

Liver cancer is a heterogeneous disease characterized by poor responses to standard therapies and therefore unfavourable clinical outcomes. Understanding the characteristics of liver cancer and developing novel therapeutic strategies are imperative. Ferroptosis, a type of programmed cell death induced by lipid peroxidation, has emerged as a potential target for treatment. Naringenin, a natural compound that modulates lipid metabolism by targeting AMPK, shows promise in enhancing the efficacy of ferroptosis inducers. In this study, we utilized liver cancer cell lines and xenograft mice to explore the synergistic effects of naringenin in combination with ferroptosis inducers, examining both phenotypic outcomes and molecular mechanisms. Our study results indicate that the use of naringenin at non-toxic doses to hepatocytes can significantly enhance the anticancer effects of ferroptosis inducers (erastin, RSL3, and sorafenib). The combination index method confirmed a synergistic effect between naringenin and ferroptosis inducers. In comparison to naringenin or ferroptosis inducers alone, the combined therapy caused more robust lipid peroxidation and hence more severe ferroptotic damage to cancer cells. The inhibition of aerobic glycolysis mediated by the AMPK-PGC1α signalling axis is the key to naringenin's effect on reducing ferroptosis resistance in liver cancer, and the synergistic cytotoxic effect of naringenin and ferroptosis inducers on cancer cells was reversed after pretreatment with an AMPK inhibitor or a PGC1α inhibitor. Taken together, these findings suggest that naringenin could boost cancer cell sensitivity to ferroptosis inducers, which has potential clinical translational value.